Page 132 - 2021年18期

a potent new TRK，ROS1，and ALK inhibitor[J]. Expert thide reactive intermediates in entrectinib metabolism：in
Opin Investig Drugs，2015，24（11）：1493-1500. vivo and in vitro metabolic investigation[J]. J Pharm
[ 4 ] AL-SALAMA Z T，KEAM S J. Entrectinib：first global ap- Biomed Anal，2018，160：19-30.
proval[J]. Drugs，2019，79（13）：1477-1483. [19] ARDINI E，MENICHINCHERI M，BANFI P，et al. En-
[ 5 ] TAKEUCHI K，SODA M，TOGASHI Y，et al. RET，ROS1 trectinib，a pan-TRK，ROS1，and ALK inhibitor with acti-
and ALK fusions in lung cancer[J]. Nat Med，2012，18 vity in multiple molecularly defined cancer indications[J].
（3）：378-381. Mol Cancer Ther，2016，15（4）：628-639.
[ 6 ] VAISHNAVI A，CAPELLETTI M，LE A T，et al. Onco- [20] LIU D，OFFIN M，HARNICAR S，et al. Entrectinib：an
genic and drug-sensitive NTRK1 rearrangements in lung orally available，selective tyrosine kinase inhibitor for the
cancer[J]. Nat Med，2013，19（11）：1469-1472. treatment of NTRK，ROS1，and ALK fusion-positive solid
[ 7 ] BRODEUR G M，MINTURN J E，HO R，et al. TRK re- tumors[J]. Ther Clin Risk Manag，2018，14：1247-1252.
ceptor expression and inhibition in neuroblastomas[J]. [21] MENICHINCHERI M，ARDINI E，MAGNAGHI P，et al.
Clin Cancer Res，2009，15（10）：3244-3250. Discovery of entrectinib：a new 3-aminoindazole as a po-
[ 8 ] AISNER D L，NGUYEN T T，PASKULIN D D，et al. tent anaplastic lymphoma kinase（ALK），c-ros oncogene
ROS1 and ALK fusions in colorectal cancer，with evi- 1 kinase（ROS1），and pan-tropomyosin receptor kinases
dence of intratumoral heterogeneity for molecular dri- （pan-TRKs）inhibitor[J]. J Med Chem，2016，59（7）：3392-
vers[J]. Mol Cancer Res，2014，12（1）：111-118. 3408.
[ 9 ] ZHANG Q，WU C，DING W，et al. Prevalence of ROS1 [22] ARDINI E，MENICHINCHERI M，BANFI P，et al. Ab-
fusion in Chinese patients with non-small cell lung can- stract A232：in vitro and in vivo activity of NMS-E628
cer[J]. Thorac Cancer，2019，10（1）：47-53. against ALK mutations resistant to Xalkori[J]. Mol Can-
[10] CHAO M V. Neurotrophins and their receptors：a conver- cer Ther，2011，10（supplement 1）：A232.
gence point for many signalling pathways[J]. Nat Rev [23] ANDERSON D，CIOMEI M，BANFI P，et al. Inhibition
Neurosci，2003，4（4）：299-309. of IRK-driven tumors by the pan-TRK inhibitor RXDX-
[11] DRILON A，HONG D S，Cruickshank S，et al. A phase Ⅱ 101[J]. Eur J Cancer，2014，50（6）：101.
basket study of the oral TRK inhibitor LOXO-101 in adult [24] PACENTA H L，MACY M E. Entrectinib and other ALK/
subjects with NTRK fusion-positive tumors[J/OL]. J Clin TRK inhibitors for the treatment of neuroblastoma[J].
Oncol，2016，34（15_suppl）：TPS2599[2021-03-12]. http：// Drug Des Devel Ther，2018，12：3549-3561.
doi.org/10.1093/annonc/mdw368.52. [25] PATEL M R，BAUER T M，LIU S V，et al. STARTRK-1：
[12] SGAMBATO A，CASALUCE F，MAIONE P，et al. Tar- phase 1/2a study of entrectinib，an oral pan-TRK，ROS1，
geted therapies in non-small cell lung cancer：a focus on and ALK inhibitor，in patients with advanced solid tumors
ALK/ROS1 tyrosine kinase inhibitors[J]. Expert Rev with relevant molecular alterations[J]. J Clin Oncol，2015，
Anticancer Ther，2018，18（1）：71-80. 33（15_suppl）：2596-2596.
[13] SOLOMON B J，MOK T，KIM D W，et al. First-line crizo- [26] WANG Q，FANG P，ZHENG L，et al. Quantification and
tinib versus chemotherapy in ALK-positive lung can- pharmacokinetic study of entrectinib in rat plasma using
cer[J]. N Engl J Med，2014，371（23）：2167-2177. ultra-performance liquid chromatography tandem mass
[14] SHAW A T，OU S H，BANG Y J，et al. Crizotinib in spectrometry[J]. Biomed Chromatogr，2019，33（4）：e4467.
ROS1-rearranged non-small-cell lung cancer[J]. N Engl J [27] DRILON A，SIENA S，OU S I，et al. Safety and antitumor
Med，2014，371（21）：1963-1971. activity of the multitargeted pan-TRK，ROS1，and ALK in-
[15] SHAW A T，KIM D W，MEHRA R，et al. Ceritinib in hibitor entrectinib：combined results from two phase Ⅰ
ALK-rearranged non-small-cell lung cancer[J]. N Engl J trials （ALKA-372-001 and STARTRK-1） [J]. Cancer
Med，2014，370（13）：1189-1197. Discov，2017，7（4）：400-409.
[16] OU S H，AHN J S，DE PETRIS L，et al. Alectinib in crizo- [28] PAZ-ARES L，DOEBELE R C，FARAGO A F，et al. En-
tinib-refractory ALK-rearranged non-small-cell lung can- trectinib in NTRK fusion-positive non-small cell lung can-
cer：a phase Ⅱ global study[J]. J Clin Oncol，2016，34 cer（NSCLC）：integrated analysis of patients（pts）enrolled
（7）：661-668. in STARTRK-2，STARTRK-1 and ALKA-372-001[J]. Ann
[17] SHAW A T，GANDHI L，GADGEEL S，et al. Alectinib in Oncol，2019，30（Supplement_2）：ii44-ii45.
ALK-positive，crizotinib-resistant，non-small-cell lung [29] DRILON A，SIENA S，DZIADZIUSZKO R，et al. Entrec-
cancer：a single-group，multicentre，phase 2 trial[J]. tinib in ROS1 fusion-positive non-small-cell lung cancer：
Lancet Oncol，2016，17（2）：234-242. integrated analysis of three phase 1-2 trials[J]. Lancet On-
[18] ATTWA M W，KADI A A，ALRABIAH H，et al. LC-MS/ col，2020，21（2）：261-270.
MS reveals the formation of iminium and quinone me- [30] HEIGENER D F，RECK M. Crizotinib[J]. Recent Results

·2298 · China Pharmacy 2021 Vol. 32 No. 18 中国药房 2021年第32卷第18期